CLNN Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
Clene Inc. had $0.2M of revenue in fiscal 2025, down 41.5% on the year before. Over five years, revenue changed β0.6% a year on average.
Last close Β· Oct 23, 2026
$3.88
0.0%Hi! I read Clene Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β41.5%
No. Sales fell 41.5% last year.
Does it make a profit?
β13,086.5%
No. It lost money last year.
Does profit turn into cash?
β9,292.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Clene Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 18 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 14, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 11, 2026 | Q1 '26 | Time not announced | 8-K β |
| Mar 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Oct 14, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 13, 2025 | Q2 '25 | Time not announced | 8-K β |
| May 6, 2025 | Q1 '25 | Time not announced | 8-K β |
| Mar 24, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 13, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Clene Inc. had $0.2M of revenue in fiscal 2025, down 41.5% on the year before. Over five years, revenue changed β0.6% a year on average. Its operating margin was β11,541.5%, down 1,865.2Β pts: of every 100 in sales, about β11,542 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Clene Inc. lost $26.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$18.6M in fiscal 2025, β9,292.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Clene Inc. owes $12.6M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Clene Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $50.3M | $23.3M | $35.0M | $12.2M | $5.2M |
| Debt incl. finance leases | β | β | β | β | $17.8M |
| Interest coverage | β57.4x | β14.7x | β8.9x | β8.1x | β8.6x |
| Current ratio | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
| Quick ratio | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
| Total assets | $63.1M | $44.5M | $52.3M | $27.3M | $18.1M |
| Total liabilities | $50.5M | $41.3M | $39.0M | $36.2M | $35.7M |
| Shareholders' equity | $12.6M | $3.2M | $13.4M | β$8.9M | β$17.6M |
| Net debt (β = net cash) | β | β | β | β | $12.6M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Clene Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 3 / 7 | 1 / 7 | 2 / 7 | 3 / 7 | 1 / 7 |
| Accruals ratio | β19.9% | β0.8% | 37.9% | 16.9% | β39.9% | β45.4% | β33.5% |
| Altman Z'' | β27.47 | β4.39 | β8.45 | β19.12 | β18.27 | β40.63 | β65.16 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | β | $0.2M | $0.7M | $0.5M | $0.7M | $0.3M | $0.2M |
| Net interest income | β | β | β$0.9M | β$3.3M | β | β | β |
| Gross profit | β | β | $0.4M | $0.4M | $0.5M | $0.3M | $0.2M |
| Research and development | $9.6M | $15.2M | $28.4M | $31.9M | $26.7M | $20.1M | $14.0M |
| Operating income | β$16.3M | β$20.2M | β$50.0M | β$48.4M | β$40.5M | β$33.1M | β$23.1M |
| Interest expense | $0.1M | $1.0M | $0.9M | $3.3M | $4.6M | $4.1M | $2.7M |
| Pretax income | β$16.2M | β$18.9M | β$10.2M | β$29.9M | β$49.5M | β$39.4M | β$26.2M |
| Income tax | β | $0.4M | β$0.4M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$16.2M | β$19.3M | β$9.7M | β$29.9M | β$49.5M | β$39.4M | β$26.2M |
| Diluted EPS | β$0.93 | β$1.10 | β$0.16 | β | β | β | β |
| Diluted shares | 0.02B | 0.02B | 0.06B | β | β | β | β |
| Cash flow | |||||||
| Cash from operations | β$13.2M | β$18.9M | β$34.6M | β$39.0M | β$30.2M | β$21.3M | β$18.5M |
| Capital expenditure | $0.3M | $0.4M | $1.3M | $5.2M | $0.3M | $0.0M | $0.0M |
| Free cash flow | β$13.5M | β$19.3M | β$36.0M | β$44.2M | β$30.5M | β$21.3M | β$18.6M |
| Depreciation and amortization | $0.8M | $1.0M | $1.0M | $1.0M | $1.7M | $1.6M | $1.5M |
| Stock-based compensation | $0.4M | $0.8M | $12.4M | $8.5M | $9.1M | $8.0M | $6.4M |
| Balance sheet | |||||||
| Cash and short-term investments | $8.8M | $59.3M | $50.3M | $23.3M | $35.0M | $12.2M | $5.2M |
| Total debt | β | $5.9M | β | β | β | β | $17.8M |
| Finance lease liabilities | β | β | β | $0.1M | $0.0M | β | β |
| Current assets | $9.5M | $63.0M | $54.6M | $29.2M | $38.9M | $16.2M | $9.0M |
| Current liabilities | $4.3M | $11.7M | $6.0M | $13.9M | $25.3M | $10.3M | $10.8M |
| Inventory | $0.0M | $0.2M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M |
| Property and equipment, net | $4.3M | $4.2M | $5.2M | β | β | β | β |
| Total assets | $14.9M | $68.2M | $63.1M | $44.5M | $52.3M | $27.3M | $18.1M |
| Total liabilities | $10.0M | $67.9M | $50.5M | $41.3M | $39.0M | $36.2M | $35.7M |
| Shareholders' equity | β$67.8M | $0.3M | $12.6M | $3.2M | $13.4M | β$8.9M | β$17.6M |
| Margins | |||||||
| Gross margin | β | β | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Operating margin | β | β9,812.6% | β6,912.6% | β10,234.5% | β6,198.8% | β9,676.3% | β11,541.5% |
| EBITDA margin | β | β9,345.1% | β6,780.5% | β10,019.0% | β5,938.1% | β9,195.3% | β10,794.0% |
| Net margin | β | β9,357.8% | β1,347.2% | β6,325.2% | β7,569.4% | β11,520.5% | β13,086.5% |
| FCF margin | β | β9,376.7% | β4,973.2% | β9,342.5% | β4,663.8% | β6,240.1% | β9,292.5% |
| Net interest share of revenue | β | β | β120.3% | β696.8% | β | β | β |
| Returns | |||||||
| Return on capital employed | β154.6% | β35.7% | β87.6% | β158.0% | β150.1% | β194.1% | β313.8% |
| Return on equity | β | β | β150.6% | β377.9% | β595.5% | β1,738.4% | β |
| Return on assets | β108.6% | β46.4% | β14.8% | β55.6% | β102.2% | β98.9% | β115.1% |
| Return on tangible equity | β | β5,653.1% | β77.3% | β924.3% | β369.7% | β | β |
| Growth | |||||||
| Revenue growth | β | β | 251.0% | β34.6% | 38.3% | β47.7% | β41.5% |
| Share count change | β | 0.8% | 251.7% | β | β | β | β |
| Financial health | |||||||
| Debt / equity | β | 17.4x | β | β | β | β | β |
| Interest coverage | β185.6x | β21.3x | β57.4x | β14.7x | β8.9x | β8.1x | β8.6x |
| Current ratio | 2.2x | 5.4x | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
| Quick ratio | 2.2x | 5.4x | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
| Capital allocation | |||||||
| Capex / revenue | β | 187.9% | 184.2% | 1,094.9% | 50.5% | 4.4% | 19.5% |
| Stock comp / revenue | β | 369.4% | 1,712.9% | 1,799.8% | 1,394.0% | 2,325.4% | 3,191.0% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 3.0 | 1.0 | 2.0 | 3.0 | 1.0 |
| Altman Z'' | β27.5 | β4.4 | β8.5 | β19.1 | β18.3 | β40.6 | β65.2 |
| Accruals ratio | β19.9% | β0.8% | 37.9% | 16.9% | β39.9% | β45.4% | β33.5% |
Source: SEC EDGAR XBRL filings (CIK 0001822791). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
